Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.56 USD | +11.28% | +3.17% | +17.93% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 887M |
---|---|---|---|---|---|
Net income 2024 * | -173M | Net income 2025 * | -171M | EV / Sales 2024 * | - |
Net Debt 2024 * | 952K | Net Debt 2025 * | 13.89M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.37
x | P/E ratio 2025 * |
-6.21
x | Employees | 72 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.67% |
Latest transcript on ALX Oncology Holdings Inc.
1 day | +11.28% | ||
1 week | +3.17% | ||
Current month | +3.17% | ||
1 month | +43.58% | ||
3 months | +16.68% | ||
6 months | +92.54% | ||
Current year | +17.93% |
Managers | Title | Age | Since |
---|---|---|---|
Jaume Pons
FOU | Founder | 58 | 15-03-31 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 20-03-31 |
Peter García
DFI | Director of Finance/CFO | 62 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
J. Garland
BRD | Director/Board Member | 55 | 22-11-27 |
Corey Goodman
CHM | Chairman | 72 | 15-02-28 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 20-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 0 M€ | +8.42% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 17.56 | +11.28% | 950,245 |
24-05-06 | 15.78 | +2.73% | 976,158 |
24-05-03 | 15.36 | -7.58% | 1,284,838 |
24-05-02 | 16.62 | -1.89% | 494,357 |
24-05-01 | 16.94 | -0.47% | 424,667 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.93% | 887M | |
+10.44% | 107B | |
+0.82% | 106B | |
+6.72% | 23.47B | |
-13.89% | 21.9B | |
-6.64% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B |
- Stock Market
- Equities
- ALXO Stock